SA518400666B1 - طريقة لإنتاج مشتق داي فينيل ميثان - Google Patents

طريقة لإنتاج مشتق داي فينيل ميثان Download PDF

Info

Publication number
SA518400666B1
SA518400666B1 SA518400666A SA518400666A SA518400666B1 SA 518400666 B1 SA518400666 B1 SA 518400666B1 SA 518400666 A SA518400666 A SA 518400666A SA 518400666 A SA518400666 A SA 518400666A SA 518400666 B1 SA518400666 B1 SA 518400666B1
Authority
SA
Saudi Arabia
Prior art keywords
formula
compound
reaction
alkyl
butyllithium
Prior art date
Application number
SA518400666A
Other languages
Arabic (ar)
English (en)
Inventor
- جونج بارك إون
- سونج يون جي
أوك بارك سو
تشوي سونجيو
بارك سي-هوان
- سيوب سونج كوانج
جو كيم مين
جيونج سيو هي
يون هي-كيون
كونج يونجيو
Original Assignee
.دايوونج فارماسوتيكال كو.، ليمتد
جرين كروس كوربوريشن
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA518400666(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by .دايوونج فارماسوتيكال كو.، ليمتد, جرين كروس كوربوريشن filed Critical .دايوونج فارماسوتيكال كو.، ليمتد
Publication of SA518400666B1 publication Critical patent/SA518400666B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00—Introduction of protecting groups or activating groups, not provided for in the preceding groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SA518400666A 2016-06-17 2018-12-15 طريقة لإنتاج مشتق داي فينيل ميثان SA518400666B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160075910 2016-06-17
PCT/KR2017/006271 WO2017217792A1 (ko) 2016-06-17 2017-06-15 다이페닐메탄 유도체의 제조방법

Publications (1)

Publication Number Publication Date
SA518400666B1 true SA518400666B1 (ar) 2021-11-30

Family

ID=60664449

Family Applications (2)

Application Number Title Priority Date Filing Date
SA518400666A SA518400666B1 (ar) 2016-06-17 2018-12-15 طريقة لإنتاج مشتق داي فينيل ميثان
SA521422474A SA521422474B1 (ar) 2016-06-17 2018-12-15 طريقة لإنتاج مشتق داي فينيل ميثان

Family Applications After (1)

Application Number Title Priority Date Filing Date
SA521422474A SA521422474B1 (ar) 2016-06-17 2018-12-15 طريقة لإنتاج مشتق داي فينيل ميثان

Country Status (29)

Country Link
US (2) US10640496B2 (cg-RX-API-DMAC10.html)
EP (2) EP3663292B1 (cg-RX-API-DMAC10.html)
JP (4) JP6763978B2 (cg-RX-API-DMAC10.html)
KR (2) KR102233229B1 (cg-RX-API-DMAC10.html)
CN (2) CN113651803B (cg-RX-API-DMAC10.html)
AU (1) AU2017285813B2 (cg-RX-API-DMAC10.html)
CA (2) CA3026756C (cg-RX-API-DMAC10.html)
CL (1) CL2018003645A1 (cg-RX-API-DMAC10.html)
CO (1) CO2018014018A2 (cg-RX-API-DMAC10.html)
DK (2) DK3663292T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2018000287A (cg-RX-API-DMAC10.html)
EC (1) ECSP19000185A (cg-RX-API-DMAC10.html)
ES (2) ES2891825T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20211670T8 (cg-RX-API-DMAC10.html)
HU (1) HUE056428T2 (cg-RX-API-DMAC10.html)
MA (2) MA50774B1 (cg-RX-API-DMAC10.html)
MX (2) MX392177B (cg-RX-API-DMAC10.html)
MY (1) MY203941A (cg-RX-API-DMAC10.html)
NZ (1) NZ749398A (cg-RX-API-DMAC10.html)
PE (2) PE20190467A1 (cg-RX-API-DMAC10.html)
PH (1) PH12018550206A1 (cg-RX-API-DMAC10.html)
PL (2) PL3663292T3 (cg-RX-API-DMAC10.html)
PT (2) PT3473621T (cg-RX-API-DMAC10.html)
RS (1) RS62550B1 (cg-RX-API-DMAC10.html)
SA (2) SA518400666B1 (cg-RX-API-DMAC10.html)
SG (2) SG11201811154QA (cg-RX-API-DMAC10.html)
SI (1) SI3663292T1 (cg-RX-API-DMAC10.html)
TN (1) TN2018000437A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017217792A1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011054773A1 (de) 2011-10-25 2013-04-25 Vb Autobatterie Gmbh & Co. Kgaa Anschlusspol für einen Akkumulator, Akkumulatorgehäuse und Maschine zur Herstellung eines Anschlusspols
BR112021002523A2 (pt) 2018-08-13 2021-05-04 Daewoong Pharmaceutical Co., Ltd. método para preparar um composto
CN112341416A (zh) * 2019-08-09 2021-02-09 天津津艺医药科技发展有限责任公司 一种制备苯并含氧脂杂环衍生物的方法
US12497390B2 (en) 2020-02-27 2025-12-16 Daewoong Pharmaceutical Co., Ltd. Intermediate useful for synthesis of SGLT inhibitor and method for preparing SGLT inhibitor using same
CN112094253B (zh) * 2020-09-10 2023-01-10 株式会社大熊制药 用于制备sglt抑制剂中间体的合成方法
WO2022051980A1 (zh) * 2020-09-10 2022-03-17 广东莱佛士制药技术有限公司 用于制备sglt抑制剂中间体的合成方法
CN113200860B (zh) * 2021-04-29 2024-07-30 爱斯特(成都)生物制药股份有限公司 一种sglt2抑制剂中间体的制备方法
KR20230046784A (ko) * 2021-09-30 2023-04-06 주식회사 대웅제약 이나보글리플로진을 포함하는 약학 조성물
CN113801010A (zh) * 2021-11-18 2021-12-17 山东诚创蓝海医药科技有限公司 一种5-溴-2-氯苯甲酸的制备方法
CN113912487B (zh) * 2021-11-23 2024-05-28 山东研峰新材料科技有限公司 一种2,5-双卤代苯甲酸的合成方法
KR102994906B1 (ko) * 2022-01-14 2026-07-24 주식회사 대웅제약 Sglt 저해제의 합성에 유용한 중간체의 제조 방법
KR20240044194A (ko) * 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 공결정
KR20240044190A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 결정형 및 이의 제조방법
WO2024072079A1 (ko) 2022-09-29 2024-04-04 주식회사 대웅제약 이나보글리플로진을 포함하는 심혈관 노화 질환 예방 또는 치료용 약학 조성물
US20260130933A1 (en) 2022-10-05 2026-05-14 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition for prevention or treatment of nephropathy and/or diabetes mellitus, comprising enavogliflozin
AU2023412900A1 (en) 2022-12-21 2025-06-12 Daewoong Therapeutics Inc. Eye drop-type pharmaceutical composition containing envogliflozin
KR20240107660A (ko) * 2022-12-30 2024-07-09 주식회사 대웅제약 이나보글리플로진 및 메트포르민을 포함하는 약학 조성물
CN122438688A (zh) 2023-12-27 2026-07-21 株式会社大熊制药 包含依那格列净作为活性成分的用于预防或治疗斑秃的药物组合物
KR102837941B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) Inline quenching 공정을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102837948B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) 분배 투입법을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102853437B1 (ko) * 2024-11-13 2025-09-04 대웅바이오(주) 연속반응 공정을 이용한 이나보글리플로진 합성방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966907A (en) * 1988-08-12 1990-10-30 Merck & Co., Inc. 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis
CN104109155A (zh) * 2003-08-01 2014-10-22 田边三菱制药株式会社 新颖化合物
UA107175C2 (uk) 2007-07-26 2014-12-10 Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
BRPI0916395A2 (pt) 2008-07-30 2016-02-16 Ferrer Int compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2012041898A1 (en) * 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
JP5876570B2 (ja) * 2011-06-01 2016-03-02 グリーン・クロス・コーポレイションGreen Cross Corp. Sglt2阻害剤としての新規のジフェニルメタン誘導体
US9340521B2 (en) 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
WO2017217792A1 (ko) 2017-12-21
RU2021129636A (ru) 2021-11-22
JP2021152054A (ja) 2021-09-30
CO2018014018A2 (es) 2019-03-08
KR102233229B1 (ko) 2021-03-29
CL2018003645A1 (es) 2019-03-22
JP2020117528A (ja) 2020-08-06
JP7773506B2 (ja) 2025-11-19
MA50774B1 (fr) 2022-02-28
NZ749398A (en) 2020-01-31
JP2019521985A (ja) 2019-08-08
MX2021008988A (es) 2022-05-05
MY203941A (en) 2024-07-25
EP3473621B1 (en) 2021-08-04
JP7669206B2 (ja) 2025-04-28
CA3081033A1 (en) 2017-12-21
MX392177B (es) 2025-03-19
PE20240590A1 (es) 2024-03-21
KR20210036892A (ko) 2021-04-05
MA44545B2 (fr) 2020-11-30
PT3473621T (pt) 2021-10-04
PL3663292T3 (pl) 2022-01-17
MX385640B (es) 2025-03-18
AU2017285813A1 (en) 2019-01-17
PL3473621T3 (pl) 2022-01-10
JP6763978B2 (ja) 2020-09-30
HUE056428T2 (hu) 2022-02-28
MA44545B1 (fr) 2020-05-29
ECSP19000185A (es) 2019-01-31
CN109311861B (zh) 2021-08-24
CA3026756A1 (en) 2017-12-21
SG10201911782RA (en) 2020-02-27
KR20170142904A (ko) 2017-12-28
JP7352509B2 (ja) 2023-09-28
SI3663292T1 (sl) 2022-01-31
RS62550B1 (sr) 2021-12-31
TN2018000437A1 (en) 2020-06-15
CA3081033C (en) 2022-04-12
CA3026756C (en) 2021-03-02
KR102379584B1 (ko) 2022-03-29
RU2019101056A3 (cg-RX-API-DMAC10.html) 2020-07-17
ES2898336T3 (es) 2022-03-07
RU2019101056A (ru) 2020-07-17
JP2023145481A (ja) 2023-10-11
US10889574B2 (en) 2021-01-12
MA50774A1 (fr) 2021-03-31
EP3473621A1 (en) 2019-04-24
CN113651803A (zh) 2021-11-16
ES2891825T3 (es) 2022-01-31
MA44545A1 (fr) 2019-10-31
CN113651803B (zh) 2022-10-28
EP3473621A4 (en) 2020-03-11
BR112018076243A2 (pt) 2019-03-26
PE20190467A1 (es) 2019-04-04
MX2018015647A (es) 2019-04-11
HRP20211670T1 (hr) 2022-02-18
SA521422474B1 (ar) 2023-11-02
AU2017285813B2 (en) 2020-02-06
CN109311861A (zh) 2019-02-05
DK3473621T3 (da) 2021-09-06
PH12018550206A1 (en) 2019-09-30
US20190382390A1 (en) 2019-12-19
DK3663292T3 (da) 2021-10-25
HRP20211670T8 (hr) 2022-03-18
SG11201811154QA (en) 2019-01-30
EP3663292B1 (en) 2021-09-01
US10640496B2 (en) 2020-05-05
DOP2018000287A (es) 2019-03-31
PT3663292T (pt) 2021-11-08
US20190169174A1 (en) 2019-06-06
EP3663292A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
EP3473621B1 (en) Method for producing diphenylmethane derivative
JP5485237B2 (ja) スピロケタール誘導体の結晶およびその製造方法
US20260078109A1 (en) Method for preparing sglt inhibitor
BR112021010927A2 (pt) Sais de amônio quaternário como inibidores da produção de trimetilamina
KR102307475B1 (ko) Sglt 저해제의 합성에 유용한 중간체의 제조
KR20090101453A (ko) 2-니트로이미다졸 유도체의 제조법
RU2814846C1 (ru) Способ получения производного дифенилметана
RU2774998C2 (ru) Способ получения производного дифенилметана
RU2797392C2 (ru) Способ получения производного дифенилметана
BR112018076243B1 (pt) Método para produzir um composto derivado de difenil metano e forma cristalina do composto produzido pelo dito método
HK40002293B (en) Method for producing diphenylmethane derivative
HK40002293A (en) Method for producing diphenylmethane derivative